February 24, 2026

AbbVie announces $380m investment in North Chicago API facilities

​AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its current...

February 23, 2026

Biocomposites to launch Synicem in UK for orthopaedic applications

​Biocomposites is set to launch its Synicem bone cement products in the UK with immediate effect for orthopaedic surgeries.The post...

February 23, 2026

J&J reports long-term QUASAR data for Tremfya in ulcerative colitis

​J&J has reported new findings from the QUASAR long-term extension study of Tremfya (guselkumab) for ulcerative colitis (UC).The post J&J...

February 23, 2026

Roche receives FDA acceptance for giredestrant combo NDA

​Roche has obtained acceptance from the US FDA for its NDA submitted for giredestrant, an oral therapy, along with everolimus...

February 20, 2026

AngioDynamics expands European indications for NanoKnife system 

​AngioDynamics has expanded indications across Europe for its NanoKnife System to include soft tissue ablation.The post AngioDynamics expands European indications...

February 20, 2026

Serina Therapeutics enrols first patient for SER-252 trial

​Serina Therapeutics has enrolled the first patient in its Phase Ib registrational trial of SER-252 for advanced Parkinson’s disease (PD).The...

February 20, 2026

Syngene and VivaMed collaborate on therapeutic programmes

​Syngene International has entered a strategic collaboration with VivaMed BioPharma to advance AI-derived repurposed therapeutic programmes.The post Syngene and VivaMed...

February 19, 2026

NG Biotech announces FDA approval for diagnostic assays

​NG Biotech and Hardy Diagnostics have received the US FDA breakthrough device designation for two rapid diagnostic assays, NG-TEST Candida...

February 19, 2026

Novartis’ RemIND trial of oral remibrutinib meets primary endpoint

​Novartis has reported that its pivotal Phase III RemIND trial, evaluating oral remibrutinib in CIndU, achieved primary endpoint.The post Novartis’...

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.